RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 people with advanced head and neck cancer that has spread or come back after immunotherapy stopped working. One group gets standard chemo plus cetuximab, another gets chemo plus bevacizumab, and a third gets bevacizumab pl…
Matched conditions: RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
Could a Blood-Flow blocker boost chemo for head and neck cancer?
Disease control OngoingThis study tested whether adding the drug bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 400 adults took part. The goal was to see if the combination helped them live longer. Bevacizumab works by cutting off the tumo…
Matched conditions: RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:08 UTC